The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

Ascension Wisconsin recently honored Racine paramedics and the Ascension All Saints Hospital Emergency Department for their ...

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, ...

The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...

For patients with large vessel occlusion presenting between 4.5 and 24 hours, intra-arterial tenecteplase after successful thrombectomy results in improved likelihood of excellent outcome (modified ...

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

An acute stroke, like most forms of stroke, starts suddenly and worsens rapidly. Some strokes may be preceded by a transient ischemic attack (TIA), a temporary stroke that resolves before causing any ...

Tenecteplase is not a new drug—it has been widely used for years in treating heart attacks. However, its potential to replace alteplase in stroke care has gained attention due to recent clinical ...